BELLUS Health’s portfolio focuses on novel therapeutics for conditions with high unmet medical need.
Its pipeline of projects includes BLU-5937 for chronic cough and KIACTA™ for sarcoidosis. BELLUS Health also has economic interests in other partnered drug development projects.
BLU-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 is a promising best-in-class drug candidate that has the potential to help millions of chronic cough patients who do not respond to current therapies. Rights to BLU-5937 were obtained under a license agreement with the NEOMED Institute in February 2017. Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. It is estimated that, in the United States alone, more than 2.7 million patients suffer from chronic cough that is not controlled by currently available medications.
KIACTA™, a novel drug candidate, is partnered with global private equity firm Auven Therapeutics, which is evaluating the potential use of KIACTA™ for the treatment of patients suffering from active pulmonary sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in sarcoidosis. The sarcoidosis program is currently under review by Auven Therapeutics and a decision is expected to be made in the coming months.
BELLUS Health also has other partnered drug development projects, including AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.